$STTK
Shattuck Labs, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
$6.88
▲+0.88%+$0.060
Subscriptions are live. Early access $24.99/mo, or start with 5 free premium days.
Plans & pricingDonateShattuck Labs, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is STTK up today? It is at $6.88 (+0.88%), and our scanner flagged it 69 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment STTK spikes, and full due diligence on STTK — key stats, earnings, dilution and insider activity. Free.
Our scanner flagged $STTK 69 times in the last 30 days. Create a free account to track $STTK, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Here is the latest on STTK from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for STTK today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystShattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business HighlightsReported Phase 1 clinical trial results for SL-325 demonstrated a potentially best-in-mechanism profile. Key findings from the Phase 1 clinical trial include:Reported RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in patients with moderately-to-severely active Crohn's disease is expected to initiate in the third quarter of 2026.Reported SL-846 is currently being evaluated in an ongoing IND-enabling GLP toxicology study in non-human primates., from an SEC filing. Read it →Latest filingSC 13G/APassive 5%+ stake updatedAug 14, 2026 · 47 days agoAcross every filing on file, supply equal to at least 175% of the tradeable float is in play - 175% more can still be issued.
Some filings did not state a size, so these are floors.
One filing exceeds the whole float, which usually means our share count is stale. Check the filing directly.
At-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing)
18,750,000 new shares · At-the-market (ATM) program — sells new shares into the market gradually over time · About $54.9M in size · Priced at $4/share
Sources: float & market cap via Polygon · short interest via FINRA · borrow & shortability via Alpaca · SSR from Reg SHO 201 · filings & dilution via SEC EDGAR · analysts via Nasdaq.
Auto-generated from public data for research and education. Not investment advice.
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Shukla Abhinav A. Officer | Other | 12K 0.01% of company | added 14% | 99K | $43K at $3.57 | Jul 6, 26 |
Shukla Abhinav A. Officer | Sold (automatic/other) | -410 | sold 0.5% | 86K | $3K at $7.01 | Jul 2, 26 |
Shukla Abhinav A. Officer | Other | 410 | added 0.5% | 87K | $1K at $3.57 | Jul 2, 26 |
Shukla Abhinav A. Officer | Sold (automatic/other) | -100 | sold 0.1% | 86K | $707 at $7.07 | Jul 1, 26 |
Shukla Abhinav A. Officer | Other | 100 | added 0.1% | 86K | $357 at $3.57 | Jul 1, 26 |
Pandite Arundathy N. Officer | Sold (automatic/other) | -30K 0.03% of company | sold 18% | 136K | $210K at $7.01 | Jun 30, 26 |
Shukla Abhinav A. Officer | Sold (automatic/other) | -23K 0.02% of company | sold 21% | 86K | $165K at $7.08 | Jun 30, 26 |
Shukla Abhinav A. Officer | Other | 23K 0.02% of company | added 27% | 110K | $83K at $3.57 | Jun 30, 26 |
Siegall Clay B Director | Bought (open market) | +63K 0.06% of company | added 24% | 319K | $250K at $4.00 | Jun 9, 26 |
Siegall Clay B Director | Acquired (grant/award) | +128K 0.1% of company | added 100% | 256K | $138K at $1.08 | May 22, 26 |
Shukla Abhinav A. Officer | Acquired (grant/award) | +5K | added 6.3% | 86K | $6K at $1.08 | May 21, 26 |
Stout Stephen Officer | Acquired (grant/award) | +13K 0.01% of company | added 16% | 93K | $14K at $1.08 | May 15, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Blend of news sentiment, today’s move, and community votes. Not investment advice.
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Comparable names in pharmaceutical preparations, closest in size first.
Here is the latest on STTK from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for STTK today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
STTK last traded at $6.88, up 0.88% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Shattuck Labs, Inc. Common Stock (STTK) is next expected to report earnings on Thursday, November 5, 2026, about 35 days away. Earnings reports often cause large overnight gaps, so many traders manage risk around the date. The date can shift until the company officially confirms it.
The STTK Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged STTK 69 times in the last 30 days.
STTK (Shattuck Labs, Inc. Common Stock) trades on XNAS, with a market cap of about $656M in the Pharmaceutical Preparations sector.
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge STTK for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.
$STTK discussion
Sign in to ask a question or join the discussion.